Fate Therapeutics, Inc. (NASDAQ:FATE) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday.

Separately, Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Tuesday, May 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.25.

Fate Therapeutics (NASDAQ FATE) traded down 4.76% during trading on Monday, reaching $2.80. The company had a trading volume of 112,488 shares. The company’s market capitalization is $115.92 million. Fate Therapeutics has a one year low of $1.80 and a one year high of $5.68. The company has a 50-day moving average price of $3.11 and a 200 day moving average price of $3.70.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.03. The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.04 million. Fate Therapeutics had a negative net margin of 857.34% and a negative return on equity of 75.93%. Analysts expect that Fate Therapeutics will post ($1.00) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Rating Lowered by ValuEngine” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/fate-therapeutics-inc-nasdaqfate-stock-rating-lowered-by-valuengine.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in Fate Therapeutics by 11.6% in the fourth quarter. Renaissance Technologies LLC now owns 209,900 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 21,900 shares during the period. Creative Planning increased its position in Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6,000 shares during the period. Wells Fargo & Company MN increased its position in Fate Therapeutics by 926.7% in the first quarter. Wells Fargo & Company MN now owns 281,111 shares of the biopharmaceutical company’s stock valued at $1,279,000 after buying an additional 253,732 shares during the period. Bank of New York Mellon Corp increased its position in Fate Therapeutics by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 59,510 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 952 shares during the period. Finally, TFS Capital LLC acquired a new position in Fate Therapeutics during the first quarter valued at approximately $248,000. 60.74% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.